Synergistic interaction between genetics and disease on pravastatin disposition

John D. Clarke, Rhiannon N. Hardwick, April D. Lake, Andrew J. Lickteig, Michael J. Goedken, Curtis D. Klaassen, Nathan J. Cherrington

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Background & Aims A genome wide association study and multiple pharmacogenetic studies have implicated the hepatic uptake transporter organic anion transporting polypeptide-1B1 (OATP1B1) in the pharmacokinetics and musculoskeletal toxicity of statin drugs. Other OATP uptake transporters can participate in the transport of pravastatin, partially compensating for the loss of OATP1B1 in patients carrying the polymorphism. Non-alcoholic steatohepatitis (NASH) in humans and in a diet-induced rodent model alter the expression of multiple OATP transporters. Methods To determine how genetic alteration in one Oatp transporter can interact with NASH-associated changes in Oatp expression we measured the disposition of intravenously administered pravastatin in Slco1b2 knockout (Slco1b2-/-) and wild-type (WT) mice fed either a control or a methionine and choline deficient (MCD) diet to induce NASH. Results Genetic loss of Oatp1b2, the rodent ortholog of human OATP1B transporters, caused a modest increase in pravastatin plasma concentrations in mice with healthy livers. Although a diet-induced model of NASH decreased the expression of multiple hepatic Oatp transporters, it did not alter the disposition of pravastatin compared to WT control mice. In contrast, the combination of NASH-associated decrease in compensatory Oatp transporters and Oatp1b2 genetic loss caused a synergistic increase in plasma area under the curve (AUC) and tissue concentrations in kidney and muscle. Conclusions Our data show that NASH alters the expression of multiple hepatic uptake transporters which, due to overlapping substrate specificity among the OATP transporters, may combine with the pharmacogenetic loss of OATP1B1 to increase the risk of statin-induced adverse drug reactions.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalJournal of Hepatology
Volume61
Issue number1
DOIs
StatePublished - Jul 2014

Keywords

  • Adverse drug reaction
  • Myopathy
  • Non-alcoholic steatohepatitis
  • Statin

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Synergistic interaction between genetics and disease on pravastatin disposition'. Together they form a unique fingerprint.

  • Cite this

    Clarke, J. D., Hardwick, R. N., Lake, A. D., Lickteig, A. J., Goedken, M. J., Klaassen, C. D., & Cherrington, N. J. (2014). Synergistic interaction between genetics and disease on pravastatin disposition. Journal of Hepatology, 61(1), 139-147. https://doi.org/10.1016/j.jhep.2014.02.021